

Financial news for CRIS dated on 2020-06-10: Mid-Afternoon Market Update: Dow Turns Higher; Fed Keeps Rates Unchanged

Financial news for CRIS dated on 2020-06-10: 61 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CRIS dated on 2020-06-10: Mid-Day Market Update: NASDAQ Tops 10,000; Curis Shares Spike Higher

Financial news for CRIS dated on 2020-06-10: The 'Important Step' For Nano-Cap Biopharma Curis That's Sending Shares Higher

Financial news for CRIS dated on 2020-06-10: Mid-Morning Market Update: Markets Mostly Lower; United Natural Foods Earnings Beat Views

Financial news for CRIS dated on 2020-06-10: Curis shares are trading higher after the company announced that the FDA gave clearance for its IND application for CI-8993 monoclonal anti-VISTA antibody.

Financial news for CRIS dated on 2020-06-10: Curis Announces FDA Clearance Of IND Application For CI-8993 Monoclonal Anti-VISTA Antibody

Financial news for CRIS dated on 2020-06-10: 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for CRIS dated on 2020-06-10: The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset

Financial news for CRIS dated on 2020-06-10: 34 Stocks Moving in Wednesday's Pre-Market Session

Financial news for CRIS dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for CRIS dated on 2020-05-12: Curis Q1 EPS \$(0.280) Up From \$(30.000) YoY, Sales \$2.709M Beat \$2.400M Estimate

Financial news for CRIS dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for CRIS dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for CRIS dated on 2020-05-04: 20 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for CRIS dated on 2020-04-08: The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO

Financial news for CRIS dated on 2020-03-19: Curis Q4 EPS \$(0.26) Down From \$(0.18) YoY, Sales \$3.287M Beat \$2.4M Estimate

Financial news for CRIS dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for CRIS dated on 2020-02-27: Curis Reports \$30M Common Stock Purchase Deal With Aspire Capital Fund

Financial news for CRIS dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for CRIS dated on 2020-02-06: Curis And Aurigene Announce Amendment Of Collaboration For The Development And Commercialization Of CA-170

Financial news for CRIS dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for CRIS dated on 2020-01-13: Curis and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies

Financial news for CRIS dated on 2020-01-07: Curis Announces Option And License Agreement With ImmuNext For Development And Commercialization Of Anti-VISTA

Antibodies

Financial news for CRIS dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for CRIS dated on 2019-12-06: Curis Reports First Demonstration Of Targeting IRAK4 In Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study

Financial news for CRIS dated on 2019-12-06: Curis Reports Safety, Tolerability, Pharmacokinetic Data In Ongoing Phase 1 Study Of Fimepinostat In Combo With Venetoclax

Financial news for CRIS dated on 2019-11-06: 61 Biggest Movers From Yesterday

Financial news for CRIS dated on 2019-11-05: 54 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CRIS dated on 2019-11-05: Curis Q3 EPS \$(0.19) Up From \$(0.22) YoY, Sales \$2.856M Beat \$2.4M Estimate

Financial news for CRIS dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for CRIS dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for CRIS dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for CRIS dated on 2019-08-08: 90 Biggest Movers From Yesterday

Financial news for CRIS dated on 2019-08-07: 75 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CRIS dated on 2019-08-07: The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout

Financial news for CRIS dated on 2019-08-06: Curis shares are trading lower after the company reported worse-than-expected Q2 sales results.

Financial news for CRIS dated on 2019-08-06: Curis Q2 EPS \$(0.22) Up From \$(0.26) YoY, Sales \$2.094M Miss \$2.4M Estimate

Financial news for CRIS dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for CRIS dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for CRIS dated on 2019-07-18: 60 Biggest Movers From Yesterday

Financial news for CRIS dated on 2019-07-17: 58 Biggest Movers From Yesterday

Financial news for CRIS dated on 2019-07-16: 41 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CRIS dated on 2019-07-16: 52 Biggest Movers From Yesterday

Financial news for CRIS dated on 2019-07-12: 55 Biggest Movers From Yesterday

Financial news for CRIS dated on 2019-06-12: Curis Highlights Publication In Nature Cell Biology Identifying Cancer-Causing Form Of IRAK4 In Patients With AML And MDS

Financial news for CRIS dated on 2019-05-14: Curis Q1 EPS \$(0.3) Misses \$(0.18) Estimate, Sales \$1.8M Miss \$2.4M Estimate

Financial news for CRIS dated on 2019-05-14: The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

Financial news for CRIS dated on 2019-04-10: Curis Regains Compliance With Nasdaq Continued Listing Requirements

Financial news for CRIS dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for CRIS dated on 2019-03-27: The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

Financial news for CRIS dated on 2019-03-26: Curis Q4 EPS \$(0.18) Beats \$(0.21) Estimate, Sales \$2.755M Beat \$2.6M Estimate

Financial news for CRIS dated on 2019-03-26: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tues., Mar. 26, 2019

Financial news for CRIS dated on 2019-03-26: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Financial news for CRIS dated on 2019-03-26: Earnings Scheduled For March 26, 2019

Financial news for CRIS dated on 2019-03-25: What's Driving The Rally In Microcap Biotech Curis?

Financial news for CRIS dated on 2019-03-25: Curis Inc shares are trading higher after the company sold a portion of revenue royalties of Erivedge to Oberland Capital for \$65 million upfront and up to \$70.7 million in future milestone payments.

Financial news for CRIS dated on 2019-03-25: Curis Sells Portion of Erivedge Royalties to Oberland Capital For \$65M Cash Upfront and Up to \$70.7M in Royalty Payments

Financial news for CRIS dated on 2019-01-24: Curis Reports First Mesothelioma Patient Enrolled, Dosed In Phase I Study Of CA-170

Financial news for CRIS dated on 2018-12-12: The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

Financial news for CRIS dated on 2018-12-11: The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Financial news for CRIS dated on 2018-12-07: The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

Financial news for CRIS dated on 2018-12-06: The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering

Financial news for CRIS dated on 2018-11-29: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018

Financial news for CRIS dated on 2018-11-29: The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved

Financial news for CRIS dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for CRIS dated on 2018-11-28: The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings

Financial news for CRIS dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for CRIS dated on 2018-11-27: The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

Financial news for CRIS dated on 2018-11-26: Stocks Which Set New 52-Week Low The Prior Trading Session, Fri., Nov. 23, 2018

Financial news for CRIS dated on 2018-11-23: Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018

Financial news for CRIS dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for CRIS dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for CRIS dated on 2018-10-19: 50 Biggest Movers From Yesterday

Financial news for CRIS dated on 2018-10-18: 41 Stocks Moving In Thursday's Mid-Day Session

Financial news for CRIS dated on 2018-10-17: 48 Biggest Movers From Yesterday

Financial news for CRIS dated on 2018-10-16: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for CRIS dated on 2018-09-24: Curis Names James Dentzer CEO Effective Immediately, Replacing Ali Fattaey Who Is Leaving The Company

Financial news for CRIS dated on 2018-08-22: Stocks Which Set New 52-Week Low Yesterday, August 21st

Financial news for CRIS dated on 2018-08-21: Stocks Which Set New 52-Week Low Tues., Aug. 21, 2018

Financial news for CRIS dated on 2018-08-16: Stocks Which Set New 52-Week Low Yesterday, August 15th

Financial news for CRIS dated on 2018-08-15: Stocks Which Set New 52-Week Low Yesterday, August 14th

Financial news for CRIS dated on 2018-08-15: The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

Financial news for CRIS dated on 2018-08-02: The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter

Financial news for CRIS dated on 2018-08-02: Curis Q2 EPS \$(0.26) Beats \$(0.39) Estimate, Sales \$2.36M Beat \$2.34M Estimate

Financial news for CRIS dated on 2018-07-28: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for CRIS dated on 2018-07-05: Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

Financial news for CRIS dated on 2018-07-03: Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium

Financial news for CRIS dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for CRIS dated on 2018-06-26: Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

Financial news for CRIS dated on 2018-06-11: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CRIS dated on 2018-06-07: 27 Stocks Moving In Thursday's Pre-Market Session

Financial news for CRIS dated on 2018-06-04: 40 Biggest Movers From Friday

Financial news for CRIS dated on 2018-06-01: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for CRIS dated on 2018-06-01: 58 Biggest Movers From Yesterday

Financial news for CRIS dated on 2018-05-31: Hearing Suntrust Raises Price Target On Curis To \$18

Financial news for CRIS dated on 2018-05-31: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for CRIS dated on 2018-05-31: Benzinga Pro's 5 Stocks To Watch Today

Financial news for CRIS dated on 2018-05-31: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for CRIS dated on 2018-05-31: Curis Reports FDA Fast Track Designation For CUDC-907 Development In Patients With Relapse, Refractory Diffuse Large B-Cell Lymphoma

Financial news for CRIS dated on 2018-05-30: 30 Stocks Moving In Wednesday's Mid-Day Session

Financial news for CRIS dated on 2018-05-29: Curis Announces 1-for-5 Reverse Split to Go Into Effect 5pm ET Today

Financial news for CRIS dated on 2018-05-22: Curis 8-K Shows Board Approved 1-For-5 Reverse Stock Split Effective Tues., May 29, '18

Financial news for CRIS dated on 2018-05-03: Curis Q1 EPS \$(0.07) Beats \$(0.09) Estimate, Sales \$2.468M Beat \$2.32M Estimate

Financial news for CRIS dated on 2018-03-08: Curis Shares Up 24.4% Following Better-Than Expected Q4 Loss, Sales Beat

Financial news for CRIS dated on 2018-03-08: Curis Reports Q4 EPS \$(0.05) vs \$(0.09) Est., Sales \$3.3M vs \$2.4M Est.

Financial news for CRIS dated on 2018-01-17: Curis Announces Initiation of Phase 1 Trial of CA-4948

Financial news for CRIS dated on 2017-11-16: Curis Director Rubin Buys 25,000 @ Avg Price: \$0.98 -Form4

Financial news for CRIS dated on 2017-11-15: CURIS CEO Fattaey Buys 50,000 @ Avg Price: \$1.06 -Form4

Financial news for CRIS dated on 2017-11-07: Curis Reports Q3 EPS \$(0.21) vs \$(0.09) Est., Sales \$2.4M vs \$2.19M Est.

Financial news for CRIS dated on 2017-10-24: Guggenheim Initiates Coverage On Curis with Buy Rating, Announces \$7.00 Price Target

Financial news for CRIS dated on 2017-09-14: Curis Announces 20M Share Offering

Financial news for CRIS dated on 2017-09-13: Curis Announces 20M Share Offering Common Stock

Financial news for CRIS dated on 2017-08-03: Curis Reports Q2 EPS \$(0.10) vs \$(0.09) Est., Sales \$2.1M vs \$2.08M Est.

Financial news for CRIS dated on 2017-06-21: Mid-Day Market Update: Red Hat Rises After Strong Q1 Results; CIRCOR Shares Slide

Financial news for CRIS dated on 2017-05-10: Curis Spikes to High of \$2.30 on Volume

Financial news for CRIS dated on 2017-05-04: Curis Q1 EPS \$(0.11) vs \$(0.09) Est, Sales \$2.1M vs \$2.0M Est

Financial news for CRIS dated on 2017-04-17: Benzinga's Option Alert Recap From April 17

Financial news for CRIS dated on 2017-04-17: Option Alert: Curis Sep 5.0 Calls: 990 @ ASK \$0.25: 1000 traded vs 714 OI: Earnings 5/4 Before Open [est] \$2.57 Ref

Financial news for CRIS dated on 2017-03-10: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for CRIS dated on 2017-03-09: 15 Biggest Mid-Day Gainers For Thursday

Financial news for CRIS dated on 2017-03-09: Curis Reports Q4 EPS \$(0.08) vs \$(0.10) in Same Qtr. Last Year, Sales \$2.4M vs \$2.1M YoY

Financial news for CRIS dated on 2017-01-09: Curis, Aurigene Extend Exclusivity Period With \$7.5M Payment To Aurigene

Financial news for CRIS dated on 2016-11-28: 12 Biggest Mid-Day Losers For Monday

Financial news for CRIS dated on 2016-11-28: 16 Stocks Moving In Monday's Pre-Market Session

Financial news for CRIS dated on 2016-11-28: Curis Announces Full Approval of Roche's Erivedge in the European Union

Financial news for CRIS dated on 2016-11-09: Curis to Offer Early Clinical Pharmacokinetic, Biomarker Data from CA-170 Phase I Trial at SITC Conference

Financial news for CRIS dated on 2016-11-03: Curis Reports Q3 EPS \$(0.21) vs. Est. \$(0.10), Rev. \$1.8M vs. Est. \$1.84M

Financial news for CRIS dated on 2016-09-22: Mid-Morning Market Update: Markets Open Higher; AutoZone Profit Tops Estimates

Financial news for CRIS dated on 2016-09-22: 25 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for CRIS dated on 2016-09-21: 22 Stocks With Three-Day Increasing Volume

Financial news for CRIS dated on 2016-09-21: 7 Stocks Which Rallied Three Days On

Increasing Volume

Financial news for CRIS dated on 2016-09-20: 30 Stocks With Three-Day Increasing Volume

Financial news for CRIS dated on 2016-09-20: 15 Stocks Which Rallied Three Days On Increasing Volume

Financial news for CRIS dated on 2016-09-09: Aurigene Discovery Technologies Ltd Buys 10,208,333 Shares of Curis @\$2.40/Share -Form 4

Financial news for CRIS dated on 2016-09-08: Curis Receives FDA Orphan Drug Designation for CUDC-907 for Treatment of Nuclear Protein in Testis (NUT) Midline Carcinoma

Financial news for CRIS dated on 2016-08-04: Curis Reports Q2 EPS \$(0.09) vs. Est. \$(0.09), Rev. \$1.7M vs. Est. \$2.05M

Financial news for CRIS dated on 2016-06-21: Curis Reports Dosing of First Patient in a Phase 1 Trial of CA-170

Financial news for CRIS dated on 2016-06-01: Curis Announces NDA Accepted for CA-170

Financial news for CRIS dated on 2016-05-09: Curis Q1 EPS (\$0.07) vs (\$0.08) est, Revenue \$1.73M vs \$2.3M est

Financial news for CRIS dated on 2016-05-05: Cowen & Company Assumes Curis at Outperform

Financial news for CRIS dated on 2016-04-04: Curis Reports Publication of CUDC-907 Phase 1 Trial Data in Lancet Oncology

Financial news for CRIS dated on 2016-03-01: SunTrust Robinson Humphrey Initiates Coverage on Curis at Buy, Announces \$3.00 PT

Financial news for CRIS dated on 2016-02-29: Curis Reports Q4 EPS \$(0.10) Vs Est \$(0.12), Sales \$2.1M Vs Est \$2.98M

Financial news for CRIS dated on 2016-01-08: 12 Biotechs With Binary Events Coming This Year

Financial news for CRIS dated on 2015-12-06: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at #ASH2015

Financial news for CRIS dated on 2015-11-09: Curis Reports Q3 EPS \$(0.04) vs \$(0.08) Est., Sales \$2.8M vs \$2.82M Est.

Financial news for CRIS dated on 2015-11-08: Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC Conference

Financial news for CRIS dated on 2015-11-05: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting

Financial news for CRIS dated on 2015-11-02: Curis Reports Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference

Financial news for CRIS dated on 2015-10-19: Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors

Financial news for CRIS dated on 2015-08-13: Curis Spikes to High on Volume

Financial news for CRIS dated on 2015-08-11: FBR Capital Initiates Coverage on Curis at Outperform, Announces \$6.00 PT

Financial news for CRIS dated on 2015-08-06: Curis Reports Inline Q2 Loss \$0.06, Sales \$2.034M

Financial news for CRIS dated on 2015-05-31: Curis Reports CUDC-907 Shows Objective Responses in Patients With Relapsed/ Refractory DLBCL from Ongoing Phase 1 Trial at ASCO

Financial news for CRIS dated on 2015-05-20: Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting

Financial news for CRIS dated on 2015-05-14: Stifel Talks 5 Biotech Stocks

Financial news for CRIS dated on 2015-05-07: Curis Reports Q1 Loss \$0.30 Vs Est Loss

\$0.06 May Not Compare Sales \$1.671M Vs Est \$2.27M

Financial news for CRIS dated on 2015-04-17: Friday's After-Hours Movers: Etsy, Cliffs Natural Resources And More

Financial news for CRIS dated on 2015-04-14: Curis to Present Data from CUDC-427, IRAK-4 Programs at AACR Annual Meeting

Financial news for CRIS dated on 2015-04-08: 5 Biotech Stocks Roth Capital Analysts Are Watching

Financial news for CRIS dated on 2015-04-06: Morning Market Gainers

Financial news for CRIS dated on 2015-04-06: Curis Announces Orphan Drug Designation For CUDC-907

Financial news for CRIS dated on 2015-03-07: Friday After-Hours Movers; Curis Inc., NovaGold Resources Inc.

Financial news for CRIS dated on 2015-02-25: Curis Prices \$60M Public Offering of Common Stock At \$2.75/share

Financial news for CRIS dated on 2015-02-24: Curis Announces Common Stock Offering; No Terms Disclosed

Financial news for CRIS dated on 2015-02-24: Why Cowen & Co Likes Celldex Therapeutics Following Its FDA 'Breakthrough'

Financial news for CRIS dated on 2015-01-28: 13G: Aurigene Discovery Reports 16.6% Stake In Curis

Financial news for CRIS dated on 2015-01-22: UPDATE: Oppenheimer Raises Price Target On Curis On Aurigene Collaboration

Financial news for CRIS dated on 2015-01-21: US Stock Futures Slip Ahead Of Housing-Starts Data

Financial news for CRIS dated on 2015-01-21: UPDATE: Curis to issue 17.1M shares of its Common Stock as Up-front Consideration

Financial news for CRIS dated on 2015-01-21: Curis, Aurigene Announce Collaboration, License, Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets

Financial news for CRIS dated on 2014-12-18: Curis Reports Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients with Advanced/Relapsed Solid Tumors

Financial news for CRIS dated on 2014-11-10: Curis, Inc. Reports Q3 EPS of \$(0.06) vs \$(0.04) Est; Revenue of \$1.76M vs \$4.13M Est

Financial news for CRIS dated on 2014-10-28: Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule

Financial news for CRIS dated on 2014-09-10: Events for the Week of Sept. 8-12

Financial news for CRIS dated on 2014-08-28: Curis CEO Fattaey Buys 62,890 Shares @ \$1.60/Share -Form 4

Financial news for CRIS dated on 2014-08-07: Curis, Inc. Reports Q2 EPS of \$(0.02) vs \$(0.05) Est; Revenue of \$4.80M vs \$3.46M Est

Financial news for CRIS dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for CRIS dated on 2014-06-03: Curis Announces Ali Fattaey President and CEO

Financial news for CRIS dated on 2014-05-08: Curis, Inc. Reports Q1 EPS of \$(0.06), Inline; Revenue of \$1.28M vs \$1.88M Est

Financial news for CRIS dated on 2014-04-08: Curis, Debiopharm Presentation Shows Debio 0932 Demonstrates Anti-tumor Activity at AACR 2014

Financial news for CRIS dated on 2014-04-07: Curis, Debiopharm Group Reports Debio 0932 Demonstrated Anti-Tumor Activity

Financial news for CRIS dated on 2014-03-31: Morning Market Movers

Financial news for CRIS dated on 2014-03-31: Curis Announces Removal of FDA Partial

Clinical Holdon CUDC-427

Financial news for CRIS dated on 2014-03-31: Curis to Present Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting

Financial news for CRIS dated on 2014-02-20: Curis, Inc. Reports Q4 EPS of \$(0.05) vs \$(0.08) Est

Financial news for CRIS dated on 2013-12-06: UPDATE: Wedbush Initiates Coverage on Curis on Potential of New Oral Therapies

Financial news for CRIS dated on 2013-12-05: Wedbush Initiates Coverage on Curis, Inc. at Outperform, Announces \$6.00 PT

Financial news for CRIS dated on 2013-11-06: Benzinga's Top #PreMarket Losers

Financial news for CRIS dated on 2013-10-06: Bret Jensen Likes Mast Therapeutics, Curis as Speculative Biotech Plays

Financial news for CRIS dated on 2013-10-04: Curis Initiates Roche-Sponsored Phase 1b/2 Study of Erivedge in Relapsed/Refractory AML and High Risk MDS

Financial news for CRIS dated on 2013-10-02: Baird Initiates Coverage on Curis, Inc. at Outperform, Announces \$7.00 PT

Financial news for CRIS dated on 2013-09-30: Chardan Capital Initiates Coverage on Curis, Inc. at Buy, Announces \$6.00 PT

Financial news for CRIS dated on 2013-08-13: Curis Strengthens Leadership Team With Appointments of Jaye Viner, M.D. as Chief Medical Officer and Tania Chander, Pharm.D. as VP of Product Development

Financial news for CRIS dated on 2013-08-05: Curis, Inc. Reports Q2 EPS of \$(0.02) vs \$(0.05) Est; Revenue of \$5.40M vs \$4.43M Est

Financial news for CRIS dated on 2013-07-25: Curis Initiates Clinical Trial of CUDC-427 In Advanced Malignancies

Financial news for CRIS dated on 2013-07-15: Curis Announces the Conditional Approval of Erivedge(R) in the European Union

Financial news for CRIS dated on 2013-06-20: Curis Announces U.S. Patent Issuance Strengthening Intellectual Property Position of PI3K-HDAC Inhibitor CUDC-907

Financial news for CRIS dated on 2013-02-20: Piper Jaffray Maintains Overweight on Curis, Inc., Lowers PT to \$6.00

Financial news for CRIS dated on 2013-02-20: Curis, Inc. Reports Q4 EPS of \$(0.15) vs \$(0.08) Est; Revenue of \$1.69M vs \$2.07M Est

Financial news for CRIS dated on 2013-02-19: Curis Names Ali Fattaey, Ph.D. as President and COO

Financial news for CRIS dated on 2013-01-03: PharmaEngine, Guangzhou BeBetter Medicine Technology Execute Collaboration and Research Agreement

Financial news for CRIS dated on 2012-12-06: Curis Issued US Patent Covering HSP90 Inhibitor Debio 0932

Financial news for CRIS dated on 2012-11-28: A Peek Into The Market Before The Trading Starts

Financial news for CRIS dated on 2012-11-28: Curis Announces Worldwide Licensing Rights for IAP Inhibitor GDC-0917 From Genentech

Financial news for CRIS dated on 2012-11-14: UPDATE: Stifel Nicolaus Initiates Curis at Hold on Erivedge Sales Outlook

Financial news for CRIS dated on 2012-11-14: Stifel Nicolaus Initiates Coverage on Curis at Hold

Financial news for CRIS dated on 2012-11-14: Stifel Nicolaus Initiates Coverage on Curis at Hold

Financial news for CRIS dated on 2012-08-02: Curis Reports Q2 EPS \$-0.04 vs \$-0.05 Est; Revenues \$4.35M vs \$3.21M Est

Financial news for CRIS dated on 2012-07-26: Oppenheimer Maintains Curis at Outperform, Lowers PT from \$5.50 to \$3.50

Financial news for CRIS dated on 2012-05-08: Curis Reports Q1 EPS \$0.03 vs \$0.03 Est; Revenues \$10.4M vs \$9.15M Est

Financial news for CRIS dated on 2012-05-07: Curis Announces Collaborator Roche's Submission of Erivedge for Registration With Australian Regulatory Authority

Financial news for CRIS dated on 2012-03-13: BMO Capital Markets Initiates Coverage on Curis at Outperform, Announces PT of \$8

Financial news for CRIS dated on 2012-02-16: Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

Financial news for CRIS dated on 2012-01-31: UPDATE: MLV Raises Target to \$10 on Curis

Financial news for CRIS dated on 2012-01-30: Curis Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma

Financial news for CRIS dated on 2011-12-22: Curis Announces Collaborator Roche's Submission of Marketing Authorization Application for Vismodegib

Financial news for CRIS dated on 2011-12-09: Oppenheimer Initiates Coverage on Curis with an Outperform Rating

Financial news for CRIS dated on 2011-12-09: Oppenheimer Initiates Curis at Outperform, \$6 PT

Financial news for CRIS dated on 2011-11-30: Rodman & Renshaw Reiterates Curis Market Outperform, \$6 PT

Financial news for CRIS dated on 2011-11-30: Curis Announces Agreement with The Leukemia & Lymphoma Society to Develop CUDC-907 for Lymphoma and Multiple Myeloma

Financial news for CRIS dated on 2011-11-11: Edison Investment Research Publishes Report on Curis

Financial news for CRIS dated on 2011-11-10: Rodman & Renshaw Maintains Market Outperform Rating and \$6 PT on Curis

Financial news for CRIS dated on 2011-11-09: FDA Accepts Curis' NDA; Grants Priority Review

Financial news for CRIS dated on 2011-11-09: Curis Announces FDA Acceptance and Priority Review of NDA for Vismodegib as Treatment for Advanced Basal Cell Carcinoma

Financial news for CRIS dated on 2011-09-30: Notable Put Options Activity in Curis

Financial news for CRIS dated on 2011-09-22: McNicoll, Lewis & Vlak Initiates Curis at Buy, \$8.50 PT

Financial news for CRIS dated on 2011-09-15: Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its Board of Directors

Financial news for CRIS dated on 2011-09-12: Curis Announces Submission of New Drug Application by Collaborator Genentech for Vismodegib in Advanced Basal Cell Carcinoma

Financial news for CRIS dated on 2011-08-16: Curis Announces Dosing of First Patient in Phase I CUDC-101 Head and Neck Cancer Combination Trial

Financial news for CRIS dated on 2011-07-29: Rodman & Renshaw Reiterates Curis Market Outperform, \$6 PT

Financial news for CRIS dated on 2011-06-21: Rodman & Renshaw Outperform On Curis, Inc.

Financial news for CRIS dated on 2011-04-08: Benzinga's Top Pre-Market NASDAQ Gainers (EXPE, CRIS, STX, NXPI)

Financial news for CRIS dated on 2011-04-04: Curis Announces Investigator-Initiated Phase II Study Results Presented at 102nd AACR Annual Meeting

Financial news for CRIS dated on 2011-03-21: Curis Trading Significantly Higher Today (CRIS)

Financial news for CRIS dated on 2011-03-21: Morning Market Movers (CRIS, OXPS, SMIT, TGE)

Financial news for CRIS dated on 2011-03-21: Benzinga's Top Pre-Market NASDAQ Gainers (TGE, CRIS, MGIC, VOD)

Financial news for CRIS dated on 2011-01-13: Best Biotech Stocks To Own Now (CRIS, CGEN, SPPI, IPXL)

Financial news for CRIS dated on 2011-01-11: 5 Bargain Biotech Stocks

Financial news for CRIS dated on 2010-10-18: CSC Wins \$54 Million Contract

Financial news for CRIS dated on 2010-02-12: Benzinga's Top Pre-Market Gainers (SKIL, MKTAY, CRIS, RIMM)

Financial news for CRIS dated on 2009-12-28: New 52-Week High Stocks (FSII, CGEN, MRM, CRIS)

Financial news for CRIS dated on 2009-08-10: Insurance Educational Association Enables Working Professionals to Go Back to School With Fall Semester Curriculum